Followed 107 TimesTop FollowedNASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free BLUE Stock Alerts $1.28 -0.08 (-5.88%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.4250-Day Range$0.91▼$1.7552-Week Range$0.88▼$5.53Volume7.27 million shsAverage Volume9.85 million shsMarket Capitalization$139.96 millionP/E RatioN/ADividend YieldN/APrice Target$5.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside358.6% Upside$5.87 Price TargetShort InterestHealthy31.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 50 Articles This WeekInsider TradingSelling Shares$9,503 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.78) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector319th out of 939 stocksBiological Products, Except Diagnostic Industry47th out of 158 stocks 4.2 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.87, bluebird bio has a forecasted upside of 358.6% from its current price of $1.28.Amount of Analyst Coveragebluebird bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted31.13% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bluebird bio has recently decreased by 0.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 2.9 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 50 news articles for bluebird bio this week, compared to 5 articles on an average week.Search Interest77 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows96 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 134% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,503.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to decrease in the coming year, from ($1.78) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesMarch 6, 2024 | marketbeat.comBeam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (BLUE)Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in placeMarch 2, 2024 | marketbeat.comMarketBeat Week in Review – 2/26 - 3/1 (BLUE)As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to investMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…February 29, 2024 | marketbeat.combluebird bio Stock Signals Potential to be a Multi-bagger (BLUE)Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could doFebruary 29, 2024 | marketbeat.combluebird bio Stock Signals Potential to be a Multi-baggerIt isn't often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a pop of more than 100%. Driven by a good story and other factors to help the jump happen.March 29, 2024 | businesswire.comBLUE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMarch 29, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Upgraded by StockNews.com to "Sell"March 29, 2024 | fool.comBluebird Bio Stock Has 138% Upside, According to 1 Wall Street AnalystMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 29, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for bluebird bio, Inc.'s Q1 2025 Earnings (NASDAQ:BLUE)March 29, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for bluebird bio, Inc. (NASDAQ:BLUE) Cut by WedbushMarch 29, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for bluebird bio, Inc. Cut by Analyst (NASDAQ:BLUE)March 28, 2024 | prnewswire.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEMarch 28, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of InvestorsMarch 28, 2024 | theglobeandmail.comBluebird bio, Inc. (NASDAQ: BLUE) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. for Potential Securities ViolationsMarch 28, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Price Target Lowered to $3.00 at Wells Fargo & CompanyMarch 28, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Receives "Sector Perform" Rating from Royal Bank of CanadaMarch 28, 2024 | americanbankingnews.comWedbush Comments on bluebird bio, Inc.'s Q4 2025 Earnings (NASDAQ:BLUE)March 27, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of InvestorsMarch 27, 2024 | tmcnet.comBLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEMarch 27, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring bluebird bio Through Analyst InsightsMarch 27, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of bluebird bio, Inc. (BLUE) on Behalf of InvestorsMarch 27, 2024 | businesswire.comBLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUEMarch 27, 2024 | finance.yahoo.comQ4 2023 bluebird bio Inc Earnings CallMarch 26, 2024 | msn.comGene therapy maker bluebird to restate financials after accounting errorsMarch 26, 2024 | businesswire.combluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 GuidanceMarch 25, 2024 | finance.yahoo.combluebird bio to Host Fourth Quarter and 2023 Annual Results Conference CallSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today3/29/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.87 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+358.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales38.88 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.54Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$139.96 million OptionableOptionable Beta0.75 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsaTyr PharmaNASDAQ:LIFECardiol TherapeuticsNASDAQ:CRDLCellectisNASDAQ:CLLSLENZ TherapeuticsNASDAQ:LENZMolecular PartnersNASDAQ:MOLNView All CompetitorsInsiders & InstitutionsHBK Investments L PBought 1,500,000 shares on 3/14/2024Ownership: 1.372%Vanguard Group Inc.Bought 3,157,919 shares on 3/11/2024Ownership: 8.026%Wellington Management Group LLPBought 31,473 shares on 3/5/2024Ownership: 0.561%Goldman Sachs Group Inc.Bought 515,812 shares on 3/1/2024Ownership: 1.168%Virtu Financial LLCBought 229,542 shares on 2/26/2024Ownership: 0.210%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 12 Wall Street analysts have issued 1 year target prices for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they anticipate the company's stock price to reach $5.87 in the next year. This suggests a possible upside of 358.6% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 on January 1st, 2024. Since then, BLUE shares have decreased by 7.2% and is now trading at $1.28. View the best growth stocks for 2024 here. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $13.56 million. bluebird bio had a negative trailing twelve-month return on equity of 34.32% and a negative net margin of 419.64%. bluebird bio's revenue for the quarter was up 17364.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.92) earnings per share. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.03%), Vanguard Group Inc. (8.03%), Granahan Investment Management LLC (7.39%), Norges Bank (3.65%), Palo Alto Investors LP (3.05%) and Ghisallo Capital Management LLC (2.88%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.